Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
…at least it is from my perspective as a long-term MMer and MM cancer coach. I believe that conventional chemotherapy regimens such as Velcade, Revlimid, Darzalex, etc. can kill MM. A two chemo regimen (doublet) kills more MM than a single regimen, a triple regimen kills more MM than a doublet, etc. etc.
Achieving remission after induction therapy, especially if you have minimal side effects is a great feeling. The two challenges for MMers are:
The articles linked and excerpted below spell out how intravenous vitamin-C therapy kills or will weaken myeloma exposing your cancer to being killed by cytotoxic therapies or the evidence-based nutrition, supplementation and other therapies that show results in myeloma therapy.
I have researched and written about vitamin C therapy for the myeloma survivor for years.
Your decision-making begins by learning about the full spectrum of evidence-based myeloma therapies, both conventional and non-conventional. To learn more about the Multiple Myeloma Coaching Course, click here.
If you would like to learn more about managing your MM with both conventional and non-conventional therapies, scroll down the page and post a comment. I will reply to you ASAP.
“Multiple myeloma (MM) remains a difficult to cure disease in the majority of cases. Several preclinical and clinical studies have shown that ascorbic acid in pharmacologic doses (PAA) selectively kills cancer cells while sparing normal cells. This article reveals the biological mechanism by which PAA exerts its anti-cancer effects and should lead to the development of an innovative therapy in MM…”
“Vitamin C breaks down to generate hydrogen peroxide, which can damage tissue and DNA. The new study shows that tumor cells with low levels of catalase enzyme activity are much less capable of removing hydrogen peroxide than normal cells, and are more susceptible to damage and death when they are exposed to high doses of vitamin C…
Most vitamin C therapies involve taking the substance orally. However, the UI scientists have shown that giving vitamin C intravenously — and bypassing normal gut metabolism and excretion pathways — creates blood levels that are 100 — 500 times higher than levels seen with oral ingestion. It is this super-high concentration in the blood that is crucial to vitamin C’s ability to attack cancer cells….”
“The antioxidant perhaps most widely used in complementary oncology is vitamin C, particularly by intravenous injection. In light of the recent clinical pharmacokinetic findings, the in vitro evidence of anti-tumor mechanisms and some well-documented cases of advanced cancers the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed…”
Pharmacologically-dosed ascorbic acid (PAA) selectively kills CD138+MM tumor cells derived from MM and smoldering MM (SMM)
Leukemia, lymphoma and multiple myeloma all have a robust collection of FDA approved, standard-of-care conventional therapies that your oncologist can provide. Unfortunately, these blood cancers often relapse. Once your multiple myeloma becomes resistant to conventional therapies you reach MDR. Further, all toxic conventional therapies cause short, long-term and late-stage collateral damage that may limit their use. Consider PAA aka intravenous vitamin C.
Whether you are looking for a first-line multiple myeloma therapy, integrative therapy or refractory therapy, there may come a time when you want to learn about non-conventional therapies for your blood cancer.
I was diagnosed with multiple myeloma in early 1994. I underwent several years of aggressive conventional therapies such as an autologous stem cell transplant. My oncologist told me that there was nothing more that she could do for me in September of 1997.
I have remained in complete remission from my “incurable cancer” since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation, bone health, etc.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
MM patients and survivors must look beyond convention myeloma therapies if they want to manage their myeloma for the long-term.
For more information about evidence-based, non-conventional therapies for your multiple myeloma, scroll down the page, post a question or comment and I will reply ASAP.
“Today’s myeloma therapy can help patients gain remission, but the combinations can cause their own side effects because they target normal cells as well as cancer cells. Investigators at the University of Iowa including Dr. Guido Tricot and Dr. Frank Zhan have tested mega-doses of Vitamin C in combination with the standard chemo melphalan and found that the Vitamin C can kill myeloma cells while not affecting normal cells…”
High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy.
We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iron, leads to the formation of highly reactive oxygen species (ROS) resulting in cell death. PAA selectively kills CD138+MM tumor cells derived from MM and smoldering MM (SMM) but not from monoclonal gammopathy undetermined significance (MGUS) patients. PAA alone or in combination with melphalan inhibits tumor formation in MM xenograft mice. This study shows PAA efficacy on primary cancer cells and cell lines in vitro and in vivo…
“University of Iowa researchers in the Holden Comprehensive Cancer Center Multiple Myeloma Program recently found evidence that mega doses of vitamin C delivered intravenously may offer new hope to people diagnosed with multiple myeloma. The results of their study were recently published in the international journal EBioMedicine…”